Search

Displaying results 2701 - 2710 of 7452 in total
  1. Drug

    Mexiletine

    go.drugbank.com/drugs/DB00379
    ApprovedInvestigational

    Antiarrhythmic agent pharmacologically similar to lidocaine. It may have some anticonvulsant properties.

  2. Drug

    Nesiritide

    go.drugbank.com/drugs/DB04899
    ApprovedInvestigationalWithdrawn

    Nesiritide is a medication used to treat acutely decompensated congestive heart failure with dyspnea at rest or with minimal exertion (such as talk, eating or bathing).

  3. Drug

    Atrasentan

    go.drugbank.com/drugs/DB06199
    ApprovedInvestigational

    to be approved for this condition. … [L52855] In April 2025, atrasentan was granted accelerated approval by the FDA for the reduction of proteinuria in patients with primary IgA nephropathy, becoming the first endothelin A receptor antagonist

  4. Drug

    Iobenguane sulfate I-123

    go.drugbank.com/drugs/DB09546
    Approved

    Iobenguane sulfate I-123 is a radiopharmaceutical used in gamma-scintigraphy of adrenergically inervated tissues [FDA Label].

  5. Drug

    Sipuleucel-T

    go.drugbank.com/drugs/DB06688
    ApprovedInvestigational

    Sipuleucel-T is a therapeutic cancer vaccine for prostate cancer. … It must be prepared specifically for each patient. In metastatic prostate cancer, it has extended survival by median 4.1 months (IMPACT Phase III trial data).

  6. Drug

    Lazertinib

    go.drugbank.com/drugs/DB16216
    ApprovedInvestigational

    [A264299, A264304] Lazertinib was first approved in South Korea on January 18, 2021, for the treatment of _EGFR_ T790M mutation-positive non-small cell lung cancer (NSCLC) with EGFR mutations. … [L51189] Lazertinib is used alone or in combination with other chemotherapeutic agents.[L51184]

  7. Drug

    Linifanib

    go.drugbank.com/drugs/DB06080
    Investigational

    Linifanib is intended for the treatment of hematologic malignancies and the solid tumors.

  8. Drug

    Topiroxostat

    go.drugbank.com/drugs/DB01685
    Investigational

    Topiroxostat is a selective xanthine oxidase inhibitor developed for treatment and management of hyperuricemia and gout. … Approved for therapeutic use in Japan since 2013, topiroxostat is marketed under the name Topiloric and Uriadec and is orally administered twice daily.

  9. Drug

    DFV890

    go.drugbank.com/drugs/DB16461
    Investigational

    DFV890 is under investigation in multiple clinical trials for its efficacy, safety, and tolerability across various conditions: NCT06031844 (coronary heart disease with elevated hsCRP), NCT04886258 (symptomatic

    Categories: Experimental Unapproved Treatments for COVID-19
  10. Drug

    Thalidomide

    go.drugbank.com/drugs/DB01041
    ApprovedInvestigationalWithdrawn

    It has been reintroduced and used for a number of inflammatory disorders and cancers.